This is also suitable as a joint venture or other commercial arrangement where such tests might be developed for future commercial use with a share of net revenues or royalty is paid to our company.

Biologics are medicinally large molecules created from proteins from the cells of living organisms.  They are much larger and more complex than normal medicine and require a complicated manufacturing process.  Biologics are approved by the FDA in the United States under a different approval regime. Biosimilars are drugs similar to a biological medicine eg  are  specifically designed to mimic  a biologic that’s already been developed.  According to Pfizer:

“Biologics have helped advance patient care by delivering highly effective and targeted treatment across multiple life-threatening and chronic diseases in the fields of oncology, inflammation/immunology, rheumatology, gastroenterology, diabetes, neurology, and inherited conditions.”

Quoting from a recent paper* regarding industrial biosynthetics such as enzymes the authors said  “Novel genetic techniques such as metabolic engineering, combinatorial biosynthesis and molecular breeding techniques ….. are contributing greatly to the development of improved industrial processes. ….. The sequencing of industrial microbal genomes is being carried out which bodes well for future process improvement and discovery of new industrial products.”  Such products need generation of novel genome sequences to create  industrial enzymes or other metabolites for use in environmental, recycling, catalysis, mineral & chemical processing and many other uses.

*Recombinant organisms for production  of industrial products” Adrio & Demain Bioengineered Bugs 1:2, 116-131; March/April 2010; 2010 Landes Bioscience.

If the GGF is reproducing the shapes, patterns and morphology of proteins, cells, tissues etc then if a biologist is designing a biosynthetic product eg a new antibody or drug to fight cancer, disease or viruses then it would be of great utility for the biologist to ‘draw’ the shape of macromolecule that he or she wishes and for a new ‘reverse GGF’  algorithm to give that biologist the DNA sequence suggested by the GGF process. For this reason, GGF Codeweaver algorithms are under development to take the biotic profile and develop candidate ligands for new drugs or enzymes.  A GGF Codeweaver algorithm might work as follows:

• The profile of the protein would be taken by laser or other nano testing method.
• This profile is then ‘shadowed’ by a generated GGF curve which encodes the possible GGF pixels that make up a GGF motif image to ‘shadow’ that profile.
• That GGF curve approximately captures the nearest GGF co ordinates to the profile.
• Those co ordinates then translate to a set of optimal oligopeptides or DNA sequences that are predicted to produce the target protein or to generate an aptamer.
• The set of candidate oliogopeptides or DNA sequences can be synthesized, placed on micro array trays and then tested to determine degree of match against the target receptor.

This GGF inverse method  or “Codeweaver”  could then design biosynthetics for:

• Oligopeptides to modify disease causing proteins
• Gene therapy such as modulating or inactivating defective genes causing disease.
• Immunotherapy
• Ligands or pharmacaphores for design of vaccines or medicine
• BioSynthetic products – medical, biological or industrial to create biosynthetics or biosimilars by designing enzymes with such techniques as protein evolution coupled with the new GGF Codeweaver algorithms and deep learning (AI).